- Suppliers
ADM 
Armor Pharma 
Asahi KASEI 
Ashland 
BASF 
Beneo 
Budenheim 
Captisol 
Croda 
DFE Pharma 
Excipio Chemicals 
Fuji Chemical 
Gattefossé 
Gangwal 
IOI Oleo 
Ingredient Pharm 
JRS Pharma 
Kerry 
KLK Oleo 
Lipoid 
Lubrizol Life Science Health 
MAGNESIA 
MEGGLE 
Nagase Viita 
Nordic Bioproducts 
Pfanstiehl 
pharm-a-spheres 
PMC Isochem 
Seppic 
ShinEtsu 
Sigachi 
SPI Pharma 
Südzucker 
Vikram Thermo 
Zerion Pharma
- Suppliers
ADM Armor Pharma Asahi KASEI Ashland BASF Beneo Budenheim Captisol Croda DFE Pharma Excipio Chemicals Fuji Chemical Gattefossé Gangwal IOI Oleo Ingredient Pharm JRS Pharma Kerry KLK Oleo Lipoid Lubrizol Life Science Health MAGNESIA MEGGLE Nagase Viita Nordic Bioproducts Pfanstiehl pharm-a-spheres PMC Isochem Seppic ShinEtsu Sigachi SPI Pharma Südzucker Vikram Thermo Zerion Pharma
Colon-targeted 3D-Printed mesalamine tablets: Core-shell design and in vitro/ex-vivo evaluation
Colon-targeted 3D-Printed mesalamine tablets
Abstract
Objectives
The present study is intended to develop a shell-core tablet using a hot melt extrusion (HME)-based dual-nozzle fused deposition modeling (FDM) three-dimensional (3D) printing approach. The primary objective was to establish a sustained-release colonic drug delivery system and improve mesalamine’s permeability by incorporating Vitamin E TPGS as a permeation enhancer.
Method
The study utilized Kollidon® SR for sustained release, L-100, and HPMC HME L100 for the tablet’s protective shell. Six filament formulations were tested, and the mechanical properties of the shell filaments, including the three-point bending, Hooke’s law, and stiffness, were assessed. Drug release profiles of the tablets were evaluated using the USP-II dissolution apparatus, and permeability characteristics were gauged using the non-everted intestinal sac method. Solutions containing 5% w/v mesalamine and 2.5% w/v Vitamin E TPGS were employed, with pure mesalamine as a control.
Highlights
- The core composition of the tablet included an extended-release polymer (Kollidon SR) and permeability enhancer (Vitamin E TPGS) with the drug (Mesalamine) to extend the drug release and enhance drug absorption.
- Shell composition contains dual polymer; Eudragit L-100 for pH-sensitive release in the colon at pH above 6 and HPMC HME L-100 for gel formation to prevent release in the upper GI tract.
- Shell filament produced via hot-melt extrusion (HME) and 3D printed to ensure protection of the core tablet.
Results
Optimal filament ratios were identified as 50:50 for the core and 30:70 for Eudragit L-100 to HPMC HME L100 for the shell. The resulting tablets achieved a prolonged drug release of up to 24 hours for the core. They ensured minimal drug release in the upper gastrointestinal tract (∼5% in the first 5 hours), effectively targeting the colon. Incorporating Vitamin E TPGS led to a 3.6-fold increase in mesalamine absorption compared to the control, and the addition of Kollidon® SR notably improved the flow properties of Mesalamine powder.
Conclusion
In conclusion, this innovative approach has the potential to achieve a colon-specific drug delivery system.
Read more here
Materials
Mesalamine was purchased from Fisher Scientific (Hanover Park, IL, USA). Methacrylic acid copolymer (Eudragit® L100) was donated by Degussa-Röhm Co. (Darmstadt, Germany). Affinisol HPMC HME 100LV (molecular weight = 180 kDa) was donated by Colorcon Inc. (PA, USA). Kollidon® SR and Vitamin E TPGS (d-α-tocopheryl polyethylene glycol succinate) were gifted from BASF (Ludwigshafen, Germany). Avicel® 102 (microcrystalline cellulose) was obtained from the FMC Biopolymer.
Nouf D. Alshammari, Ahmed Almotairy, Mashan Almutairi, Peilun Zhang, Esraa Al Shawakri, Sateesh Kumar Vemula, Michael A. Repka, Colon-targeted 3D-Printed mesalamine tablets: Core-shell design and in vitro/ex-vivo evaluation,
Journal of Drug Delivery Science and Technology, 2024, 105580, ISSN 1773-2247, https://doi.org/10.1016/j.jddst.2024.105580.
CPHI & PMEC China will be held at 19-21 June 2024. Register for free:
